UNSPSC 51112523: Sufosfamide

This classification denotes an antipsychotic agent with the molecular formula C8H18ClN2O5PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2208Y59985, chemically known as 3-(2-chloroethyl)-2-(2-mesyloxyethylamino)tetrahydro-2h-1,3,2-oxazaphosphorin-2-oxide but more generally known as sufosfamide, which bears US NIH Compound Identifier 65805. European Medicines Agency schedules Sufosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10672MIG.

UNSPSC 51112523 Sufosfamide, a Commodity code, identifies a single chemotherapy agent that state and local governments procure primarily through health departments, public health agencies, and state Medicaid programs for cancer treatment protocols in public clinics and correctional-facility medical units. The code covers sufosfamide as a pharmaceutical product — a nitrogen mustard alkylating agent used in combination chemotherapy regimens — rather than administration, counseling, or ancillary oncology services. Issuing bodies include state health and human services departments managing Medicaid pharmacy benefits, county health authorities, municipal public hospitals, and departments of corrections purchasing for inmate medical care.

No recent state and local contract opportunities appear in the available records for sufosfamide procurement under this code. The code shows limited recent solicitation activity in public procurement channels, suggesting that sufosfamide purchases typically flow through established pharmaceutical supply agreements, group purchasing organizations, or existing state Medicaid contracts rather than through standalone competitive procurements. Firms pursuing this code should monitor state Medicaid pharmacy notices, correctional-health purchasing updates, and cooperative purchasing vehicle catalogs for sufosfamide inclusion or formulary changes.